Protagonist Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | |
|---|---|---|---|
| | PROTAGONIST THERAPEUTICS, INC. | ||
| | | | |
| Date: February 27, 2024 | By: | | /s/ Dinesh V. Patel, Ph.D. |
| | | | Dinesh V. Patel, Ph.D. |
| | | | President, Chief Executive Officer and Director |
| | | | (Principal Executive Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dinesh V. Patel and Asif Ali, and each of them, his or her true and lawful attorneys-in-fact, with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact or any of them or their substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:
| | | | | |
|---|---|---|---|---|
| | | | | |
| Signature | Title | Date | ||
| | | | | |
| /s/ Dinesh V. Patel, Ph.D. | | President, Chief Executive Officer and Director | | February 27, 2024 |
| Dinesh V. Patel, Ph.D. | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Asif Ali | | Executive Vice President, Chief Financial Officer | | February 27, 2024 |
| Asif Ali | | (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ Harold E. Selick, Ph.D. | | Chairman of the Board of Directors | | February 27, 2024 |
| Harold E. Selick, Ph.D. | | | | |
| | | | | |
| /s/ Bryan Giraudo | | Director | | February 27, 2024 |
| Bryan Giraudo | | | | |
| | | | | |
| /s/ Sarah O’Dowd | | Director | | February 27, 2024 |
| Sarah O’Dowd | | | | |
| | | | | |
| /s/ Daniel N. Swisher, Jr. | | Director | | February 27, 2024 |
| Daniel N. Swisher, Jr. | | | | |
| | | | | |
| /s/ William D. Waddill | | Director | | February 27, 2024 |
| William D. Waddill | | | | |
| | | | | |
| /s/ Lewis T. Williams, M.D., Ph.D. | | Director | | February 27, 2024 |
| Lewis T. Williams, M.D., Ph.D. | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.